CLINICAL_TRIALS
trial_result
· 2018-12-12
Clinical Trial Update: A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer [Phase 3]
Summary
Phase 3 study of abemaciclib in previously treated KRAS-mutated non-small cell lung cancer has posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2018-12-12